Vincent L. Cannataro

Vincent L. Cannataro

Auto-generated profile, based on publicly available information

Vincent L. Cannataro

Department of Biology, Emmanuel College, Boston, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2018 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
VCVincent L Cannataro
Vincent L Cannataro
SGStephen G Gaffney
Stephen G Gaffney
Jeffrey P TownsendJeffrey P Townsend
Jeffrey P Townsend
A major goal of cancer biology is determination of the relative importance of the genetic alterations that confer selective advantage to cancer cells. Tumor sequence surveys have frequently ranked the importance of substitutions to cancer growth by P value or a false-discovery conversion thereof. However, P values are thresholds for belief, not metrics of effect. Their frequent misuse as metrics of effect has often been vociferously decried, even in cases when the only attributable mistake was omission of effect sizes. Here, we propose an appropriate ranking—the cancer effect size, which is the selection intensity for somatic variants in cancer cell lineages. The selection intensity is a metric of the survival and reproductive advantage conferred by mutations in somatic tissue. Thus, they are of fundamental importance to oncology, and have immediate relevance to ongoing decision making in precision medicine tumor boards, to the selection and design of clinical trials, to the targeted development of pharmaceuticals, and to basic research prioritization. Within this commentary, we first discuss the scope of current methods that rank confidence in the overrepresentation of specific mutated genes in cancer genomes. Then we bring to bear recent advances that draw upon an understanding of the development of cancer as an evolutionary process to estimate the effect size of somatic variants leading to cancer. We demonstrate the estimation of the effect sizes of all recurrent single nucleotide variants in 22 cancer types, quantifying relative importance within and between driver genes.

15 January 2019 in Oncogene
Verified
Journal Article
Open access
PDF file
VCVincent L. Cannataro
Vincent L. Cannataro
SGStephen G. Gaffney
Stephen G. Gaffney
TSTomoaki Sasaki
Tomoaki Sasaki
Natalia IssaevaNatalia Issaeva
Natalia Issaeva
NGNicholas K. S. Grewal
Nicholas K. S. Grewal
Jeffrey P TownsendJeffrey P Townsend
Jeffrey P Townsend
Recent studies have revealed the mutational signatures underlying the somatic evolution of cancer, and the prevalences of associated somatic genetic variants. Here we estimate the intensity of positive selection that drives mutations to high frequency in tumors, yielding higher prevalences than expected on the basis of mutation and neutral drift alone. We apply this approach to a sample of 525 head and neck squamous cell carcinoma exomes, producing a rank-ordered list of gene variants by selection intensity. Our results illustrate the complementarity of calculating the intensity of selection on mutations along with tallying the prevalence of individual substitutions in cancer: while many of the most prevalently-altered genes were heavily selected, their relative importance to the cancer phenotype differs from their prevalence and from their P value, with some infrequent variants exhibiting evidence of strong positive selection. Furthermore, we extend our analysis of effect size by quantifying the degree to which mutational processes (such as APOBEC mutagenesis) contributes mutations that are highly selected, driving head and neck squamous cell carcinoma. We calculate the substitutions caused by APOBEC mutagenesis that make the greatest contribution to cancer phenotype among patients. Lastly, we demonstrate via in vitro biochemical experiments that the APOBEC3B protein can deaminate the cytosine bases at two sites whose mutant states are subject to high net realized selection intensities—PIK3CA E545K and E542K. By quantifying the effects of mutations, we deepen the molecular understanding of carcinogenesis in head and neck squamous cell carcinoma.

20 September 2016 in Bulletin of Mathematical Biology
Verified
Journal Article
Closed access
PDF file
NTNecibe Tuncer
Necibe Tuncer
HGHayriye Gulbudak
Hayriye Gulbudak
VCVincent L. Cannataro
Vincent L. Cannataro
MMMaia Martcheva
Maia Martcheva

23 October 2019 in Molecular Biology and Evolution
Verified
Journal Article
Open access
PDF file
JSJason A Somarelli
Jason A Somarelli
HGHeather Gardner
Heather Gardner
VCVincent L Cannataro
Vincent L Cannataro
EGElla F Gunady
Ella F Gunady
ABAmy M Boddy
Amy M Boddy
Jeffrey P TownsendJeffrey P Townsend
Jeffrey P Townsend
Cancer progression is an evolutionary process. During this process, evolving cancer cell populations encounter restrictive ecological niches within the body, such as the primary tumor, circulatory system, and diverse metastatic sites. Efforts to prevent or delay cancer evolution—and progression—require a deep understanding of the underlying molecular evolutionary processes. Herein we discuss a suite of concepts and tools from evolutionary and ecological theory that can inform cancer biology in new and meaningful ways. We also highlight current challenges to applying these concepts, and propose ways in which incorporating these concepts could identify new therapeutic modes and vulnerabilities in cancer.

22 June 2020 in International Journal of Production Research
Verified
Journal Article
Closed access
NTNazli Turken
Nazli Turken
VCVincent Cannataro
Vincent Cannataro
AGAvinash Geda
Avinash Geda
ADAshutosh Dixit
Ashutosh Dixit
Supply chains are becoming increasingly complex, and many companies and researchers are looking to nature for finding solutions. In this paper, we provide a narrative synthesis and systematic review to explore state-of-the-art, and identify key areas for exploration of nature inspired solutions in the supply chain area. We consider strategic, tactical, and operational decisions within supply chains and identify analogies between biological systems and supply chains to create a new research agenda. Our findings show that the majority of the research in nature inspired supply chains from the systemic perspective focuses on closed loop supply chains. In contrast, similar systemic solutions such as industrial symbiosis, circular economy, and industrial ecology have not been explored as frequently. Reducing production waste (industrial symbiosis) in addition to end-of-life product waste (closed loop supply chains), optimising raw material use and extending the life of used resources (circular economy), investigating the interactions between biosphere and technosphere (industrial ecology), and seeking solutions to industrial problems from nature (biomimicry) are all possible paths for reaching a zero-waste economy. These systemic solutions have a considerable impact on the supply chains at the strategic, tactical, and operational levels, which need to be explored to identify efficient and effective solutions.

26 April 2022 in Molecular Biology and Evolution
Verified
Journal Article
Open access
PDF file
VCVincent L. Cannataro
Vincent L. Cannataro
JMJeffrey D. Mandell
Jeffrey D. Mandell
Jeffrey P TownsendJeffrey P Townsend
Jeffrey P Townsend
Mutational processes in tumors create distinctive patterns of mutations, composed of neutral “passenger” mutations and oncogenic drivers that have quantifiable effects on the proliferation and survival of cancer cell lineages. Increases in proliferation and survival are mediated by natural selection, which can be quantified by comparing the frequency at which we detect substitutions to the frequency at which we expect to detect substitutions assuming neutrality. Most of the variants detectable with whole-exome sequencing in tumors are neutral or nearly neutral in effect, and thus the processes generating the majority of mutations may not be the primary sources of the tumorigenic mutations. Across 24 cancer types, we identify the contributions of mutational processes to each oncogenic variant and quantify the degree to which each process contributes to tumorigenesis. We demonstrate that the origination of variants driving melanomas and lung cancers is predominantly attributable to the preventable, exogenous mutational processes associated with ultraviolet light and tobacco exposure, respectively, whereas the origination of selected variants in gliomas and prostate adenocarcinomas is largely attributable to endogenous processes associated with aging. Preventable mutations associated with pathogen exposure and apolipoprotein B mRNA-editing enzyme activity account for a large proportion of the cancer effect within head-and-neck, bladder, cervical, and breast cancers. These attributions complement epidemiological approaches—revealing the burden of cancer driven by single-nucleotide variants caused by either endogenous or exogenous, nonpreventable, or preventable processes, and crucially inform public health strategies.